TW-37: A New Treatment for B-cell Tumors
Author Information
Author(s): Al-Katib Ayad M, Sun Yuan, Goustin Anton Scott, Azmi Asfar Sohail, Chen Ben, Aboukameel Amro, Mohammad Ramzi M
Primary Institution: Wayne State University School of Medicine
Hypothesis
Can TW-37 effectively induce apoptosis in various B-cell tumors regardless of their differentiation status?
Conclusion
TW-37 shows significant activity against a range of B-cell tumors by inducing apoptosis, independent of their proliferative status.
Supporting Evidence
- TW-37 induced apoptosis in both established cell lines and fresh patient samples.
- IC50 values for TW-37 ranged from 165 nM to 320 nM across different B-cell lines.
- TW-37 showed no effect on normal peripheral blood lymphocytes.
- Significant tumor growth inhibition was observed in SCID mice treated with TW-37.
Takeaway
TW-37 is a new medicine that helps kill cancer cells in B-cell tumors, even if those tumors are at different stages of growth.
Methodology
The study evaluated TW-37's efficacy using various B-cell lines, fresh patient samples, and animal models, employing multiple assays to measure apoptosis and tumor growth.
Limitations
The study primarily focused on specific B-cell lines and patient samples, which may not represent all B-cell tumors.
Participant Demographics
Included patients with chronic lymphocytic leukemia and marginal zone lymphoma.
Statistical Information
P-Value
p ≤ 0.01
Statistical Significance
p ≤ 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website